Pedro Huertas is Chief Medical Officer of Kriya’s Rare Disease Division where he is responsible for the design and execution of the clinical, medical and scientific strategy for the company’s pipeline of rare disease gene therapies. Dr. Huertas brings three decades of experience advancing therapies for rare conditions across a spectrum of roles, including in preclinical and clinical research, clinical development, post-marketing development and regulatory strategy. Prior to joining Kriya, he served as Chief Medical Officer at Inozyme Pharma, Sentien Biotechnologies, and Eloxx Pharmaceuticals. Earlier in his career, Dr. Huertas held clinical and development leadership roles at Pfizer, Shire, Amicus and Genzyme Corp. While at Genzyme, he helped lead the successful effort to file for approval of Fabrazyme (agalsidase beta), an enzyme replacement therapy for Fabry disease, in the United States, Europe and Japan.

Source: Kriya Therapeutics, Inc. on 01/11/2023